The global genomics market is projected to grow from USD 47.07 billion in 2025 to USD 85.09 billion by 2030, at a CAGR of 12.6% during the forecast period. Market growth is being driven by increasing investments in genomics research, expansion of population genomics initiatives, and a growing focus on rare and genetic diseases.
Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=613
Advancements in next-generation sequencing (NGS) platforms, along with the expanding role of genomics in drug discovery, diagnostics, and agriculture, are significantly contributing to market expansion. In addition, the rising adoption of precision medicine is enabling healthcare providers to deliver more targeted and effective treatments, improving patient outcomes.
Products Segment Dominates Market by Offering
By offering, the products segment accounted for the largest share of the genomics market in 2024. This growth is attributed to continuous innovations in genomics technologies, including long-read sequencing (LRS), single-cell genomics, and CRISPR-based solutions.
These advancements have expanded the range of available products and applications, increasing demand for specialized reagents, kits, and instruments used across research and clinical settings.
Functional Genomics Segment to Register Highest Growth
By study type, the functional genomics segment is expected to register the highest CAGR during the forecast period. Functional genomics plays a critical role in identifying gene functions and interactions, making it essential for drug target discovery and understanding complex diseases such as cancer and genetic disorders.
Its increasing adoption in pharmaceutical and biotechnology research is driving significant growth in this segment, while biomarker discovery continues to hold the second-largest market share.
Speak To Analyst:- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=613
Asia Pacific Emerges as Fastest-Growing Region
The Asia Pacific region is projected to witness the fastest growth in the genomics market during the forecast period. This growth is supported by increasing government funding for genomic research, expanding healthcare infrastructure, and rising adoption of precision medicine initiatives.
Countries such as China, Japan, and India are experiencing strong growth due to large patient populations, increasing prevalence of chronic and genetic diseases, and growing investments from both global and regional market players.
Competitive Landscape
Key players operating in the genomics market include Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), QIAGEN (Germany), Agilent Technologies, Inc. (US), Revvity, Inc. (US), Laboratory Corporation of America Holdings (US), IQVIA Inc. (US), Charles River Laboratories (US), Bio-Rad Laboratories, Inc. (US), Eurofins Scientific (Luxembourg), PacBio (US), Oxford Nanopore Technologies Plc. (UK), Takara Bio Inc. (Japan), BGI Group (China), Eppendorf SE (Germany), Merck KGaA (Germany), BD (US), Abbott (US), 10X Genomics, Inc. (US), New England Biolabs (US), Promega Corporation (US), Creative Biogene (US), Novogene Co., Ltd. (China), Helix, Inc. (US), Phalanx Biotech Group (US), and Polaris Genomics (US), among others.
These companies are focusing on technological innovation, strategic collaborations, and expanding their global presence to capitalize on the growing demand for genomics solutions.